Prof. Sørge Kelm, Paul Madge, Dr. Tasneem Islam, Ryan Bennett, Dr. Hendrik Koliwer-Brandl, Dipl.-Chem. Mario Waespy, Prof. Mark von Itzstein and Dr. Thomas Haselhorst C-4 Modified Sialosides Enhance Binding to Siglec-2 (CD22): Towards Potent Siglec Inhibitors for Immunoglycotherapy Angewandte Chemie International Edition 52
Two changes for the better: A novel class of sialic acid derivatives is prepared by modifying both the C-4 and C-9 positions of Neu5Aα2Me (see structure). This approach gives a lead compound that has sub-micromolar affinity for Siglec-2 and may provide a pathway for immunoglycotherapy strategies for autoimmune diseases and B cell derived non-Hodgkin's lymphoma.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf